Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
About this item
Full title
Author / Creator
Herbst, Roy S , Giaccone, Giuseppe , de Marinis, Filippo , Reinmuth, Niels , Vergnenegre, Alain , Barrios, Carlos H , Morise, Masahiro , Felip, Enriqueta , Andric, Zoran , Geater, Sarayut , Özgüroğlu, Mustafa , Zou, Wei , Sandler, Alan , Enquist, Ida , Komatsubara, Kimberly , Deng, Yu , Kuriki, Hiroshi , Wen, Xiaohui , McCleland, Mark , Mocci, Simonetta , Jassem, Jacek and Spigel, David R
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Among patients with lung cancer that expressed programmed death ligand 1, the anti–PD-L1 antibody atezolizumab was compared with chemotherapy in a randomized trial. In the subgroup with the highest PD-L1 expression, the median overall survival was 20.2 months with atezolizumab and 13.1 months with chemotherapy.
Alternative Titles
Full title
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Authors, Artists and Contributors
Author / Creator
Giaccone, Giuseppe
de Marinis, Filippo
Reinmuth, Niels
Vergnenegre, Alain
Barrios, Carlos H
Morise, Masahiro
Felip, Enriqueta
Andric, Zoran
Geater, Sarayut
Özgüroğlu, Mustafa
Zou, Wei
Sandler, Alan
Enquist, Ida
Komatsubara, Kimberly
Deng, Yu
Kuriki, Hiroshi
Wen, Xiaohui
McCleland, Mark
Mocci, Simonetta
Jassem, Jacek
Spigel, David R
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2447572660
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2447572660
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1917346
